Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria E Suarez-Almazor

Showing results (81-90 of 243) with videos related to

Pageof 25
Sort By:
The Cochrane Database of Systematic Reviews|May 20, 2026
Dose reduction and discontinuation of non-tumor necrosis factor (TNF) biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for people with rheumatoid arthritis in remission or low disease activityYuanteng J Li, Maria Angeles Lopez-Olivo, Yimin Geng, et al.
BMC Rheumatology|July 2, 2025
Beliefs, preferences, and informational needs of patients with rheumatoid arthritis and concomitant cancer: a qualitative studyJuan I Ruiz, Sheneze T Madramootoo, Maria A Lopez-Olivo, et al.
Arthritis Care & Research|November 12, 2015
Link Between Positive Clinician-Conveyed Expectations of Treatment Effect and Pain Reduction in Knee Osteoarthritis, Mediated by Patient Self-EfficacyGrace Hsiao-Wei Lo, Ajay S Balasubramanyam, Andrea Barbo, et al.
Cancer|June 24, 2020
Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumabMaria E Suarez-Almazor, Raul Herrera, Xiudong Lei, et al.
Clinical Rheumatology|April 24, 2023
Smoking cessation patterns, usefulness of quitting methods, and tobacco cessation motivators and barriers to quit in patients with rheumatoid arthritisMaria A Lopez-Olivo, Kaleb Michaud, Rebecca Schumacher, et al.
The Cochrane Database of Systematic Reviews|January 21, 2015
Rituximab for rheumatoid arthritisMaria Angeles Lopez-Olivo, Matxalen Amezaga Urruela, Lynda McGahan, et al.
Immunotherapy|March 1, 2021
Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosisSang T Kim, Xerxes Pundole, Ramona Dadu, et al.
Journal of Clinical Medicine|October 27, 2022
Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for ManagementMar Riveiro-Barciela, Maria Jose Soler, Ana Barreira-Diaz, et al.
BMJ Open|July 12, 2019
Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)Line Uhrenholt, Annette Schlemmer, Ellen-Margrethe Hauge, et al.
The Journal of Rheumatology|June 18, 2013
Use of the Patient-generated Index in systemic sclerosis to assess patient-centered outcomesSofia de Achaval, Michael A Kallen, Maureen D Mayes, et al.
Pageof 25

Showing results (81-90 of 243) with videos related to

Sort By:
Pageof 25
The Cochrane Database of Systematic Reviews|May 20, 2026
Dose reduction and discontinuation of non-tumor necrosis factor (TNF) biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for people with rheumatoid arthritis in remission or low disease activityYuanteng J Li, Maria Angeles Lopez-Olivo, Yimin Geng, et al.
BMC Rheumatology|July 2, 2025
Beliefs, preferences, and informational needs of patients with rheumatoid arthritis and concomitant cancer: a qualitative studyJuan I Ruiz, Sheneze T Madramootoo, Maria A Lopez-Olivo, et al.
Arthritis Care & Research|November 12, 2015
Link Between Positive Clinician-Conveyed Expectations of Treatment Effect and Pain Reduction in Knee Osteoarthritis, Mediated by Patient Self-EfficacyGrace Hsiao-Wei Lo, Ajay S Balasubramanyam, Andrea Barbo, et al.
Cancer|June 24, 2020
Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumabMaria E Suarez-Almazor, Raul Herrera, Xiudong Lei, et al.
Clinical Rheumatology|April 24, 2023
Smoking cessation patterns, usefulness of quitting methods, and tobacco cessation motivators and barriers to quit in patients with rheumatoid arthritisMaria A Lopez-Olivo, Kaleb Michaud, Rebecca Schumacher, et al.
The Cochrane Database of Systematic Reviews|January 21, 2015
Rituximab for rheumatoid arthritisMaria Angeles Lopez-Olivo, Matxalen Amezaga Urruela, Lynda McGahan, et al.
Immunotherapy|March 1, 2021
Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosisSang T Kim, Xerxes Pundole, Ramona Dadu, et al.
Journal of Clinical Medicine|October 27, 2022
Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for ManagementMar Riveiro-Barciela, Maria Jose Soler, Ana Barreira-Diaz, et al.
BMJ Open|July 12, 2019
Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)Line Uhrenholt, Annette Schlemmer, Ellen-Margrethe Hauge, et al.
The Journal of Rheumatology|June 18, 2013
Use of the Patient-generated Index in systemic sclerosis to assess patient-centered outcomesSofia de Achaval, Michael A Kallen, Maureen D Mayes, et al.
Pageof 25